Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease.
about
Danger Signals and Graft-versus-host Disease: Current Understanding and Future PerspectivesHaploidentical hematopoietic transplantation without T-cell depletion: current status and future perspectivesSiglec-G-CD24 axis controls the severity of graft-versus-host disease in mice.Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in miceInducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantationTumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.Serum Gp96 is a chaperone of complement-C3 during graft-versus-host disease.Immunotherapeutic approaches to improve graft-versus-tumor effect and reduce graft-versus-host disease.T cell depletion in paediatric stem cell transplantation.The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.Immunotherapy for viral and fungal infections.The evolution of T-cell depletion in haploidentical stem-cell transplantation.Hsp90 inhibition ameliorates CD4(+) T cell-mediated acute Graft versus Host disease in mice.Targeting polo-like kinase 1 suppresses essential functions of alloreactive T cells.Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases Tregs.The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors.The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development.
P2860
Q28075204-0F0DEE71-3AF1-48FF-8376-B22D74482DEAQ28080452-2EACD7A0-1EA4-45EF-A744-850FD94F565FQ33697267-724B29B0-8168-4D86-829B-052A0098E203Q33707337-A315FBAE-5CE9-4E1F-AE26-EB73C1FC56FDQ35784529-B305B8A0-6A6B-43E7-AB53-25CD58D88631Q36465517-B98C8C75-A3B2-43D0-9F2A-E542BF433AD8Q37711797-BE4A8874-74E6-4008-990B-BA026220689CQ38003477-63489E24-8422-4F2F-AA6E-30777508EFEAQ38097916-1A0AEDCE-1C6C-4D61-8350-B5FA481BCD27Q38216836-F7342228-101E-4AE5-B4D1-1CABAC6B9312Q38514499-39B6BB6B-E200-45D2-A86B-6764A9BC8E92Q38673780-AF4701E6-A04B-4503-9C6A-5C43BC93DE0BQ39096609-8C1FB853-774C-45D7-9634-1D1097C25F6AQ40150859-D0C4EF09-6016-48D9-8C8B-F2A2269B45A2Q41057184-A28777AD-B7A7-44B4-B5FD-4F0F24D24881Q42082409-5BA6043C-26BD-484F-9DE2-218DE8330EAAQ53347165-06BC7A97-FD5A-4BE7-87CE-834DA1F95F39
P2860
Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Selective depletion of allorea ...... of graft-versus-host disease.
@en
Selective depletion of allorea ...... of graft-versus-host disease.
@nl
type
label
Selective depletion of allorea ...... of graft-versus-host disease.
@en
Selective depletion of allorea ...... of graft-versus-host disease.
@nl
prefLabel
Selective depletion of allorea ...... of graft-versus-host disease.
@en
Selective depletion of allorea ...... of graft-versus-host disease.
@nl
P2093
P1433
P1476
Selective depletion of allorea ...... of graft-versus-host disease.
@en
P2093
Claudia Stuehler
Florian Rueckert
Johannes Duell
Manik Chatterjee
Max S Topp
Ralf C Bargou
Sarah Lurati
P304
P356
10.1182/BLOOD-2009-06-224600
P407
P577
2009-08-05T00:00:00Z